Human platelet calcium mobilisation in response to β-amyloid (25-35):: buffer dependency and unchanged response in Alzheimer's disease

被引:10
|
作者
Hedin, HLM [1 ]
Eriksson, S
Fowler, CJ
机构
[1] Umea Univ, Dept Pharmacol & Clin Neurosci, SE-90187 Umea, Sweden
[2] Umea Univ, Dept Community Med & Rehabil, SE-90187 Umea, Sweden
关键词
Alzheimer's disease; U-73122; amyloid beta peptides; platelets; serotonin;
D O I
10.1016/S0197-0186(00)00068-1
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In the present study, the effects of beta -amyloid (25-35) (A beta (25-35)) upon calcium signalling by the human platelet has been investigated. When assays were conducted using HEPES buffers, A beta (25-35), but not the inactive peptide A beta (35-25), produced a robust increase in intracellular calcium that remained after removal of extracellular calcium but was abolished by the phospholipase C inhibitor U-73122. There was no significant difference bt tween the calcium response to A beta (25-35) in platelets from patients with Alzheimer's disease and from age-matched controls. In contrast to the robust effects on calcium mobilisation in HEPES buffers, very little calcium response to A beta (25-35) was seen when Krebs (pH 7.8) buffer was used. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:145 / 151
页数:7
相关论文
共 50 条
  • [31] Microglia receptors and their implications in the response to amyloid β for Alzheimer’s disease pathogenesis
    Deborah Doens
    Patricia L Fernández
    Journal of Neuroinflammation, 11
  • [32] Neuronal MicroRNA Deregulation in Response to Alzheimer's Disease Amyloid-β
    Schonrock, Nicole
    Ke, Yazi D.
    Humphreys, David
    Staufenbiel, Matthias
    Ittner, Lars M.
    Preiss, Thomas
    Goetz, Juergen
    PLOS ONE, 2010, 5 (06):
  • [33] Microglia receptors and their implications in the response to amyloid β for Alzheimer's disease pathogenesis
    Doens, Deborah
    Fernandez, Patricia L.
    JOURNAL OF NEUROINFLAMMATION, 2014, 11
  • [34] Investigation of plasma metabolomics and neurotransmitter dysfunction in the process of Alzheimer's disease rat induced by amyloid beta 25-35 (vol 9, pg 18308, 2019)
    Wei, Mengying
    Liu, Yuanyuan
    Pi, Zifeng
    Yue, Kexin
    Li, Shizhe
    Hu, Mingxin
    Liu, Zhiqiang
    Song, Fengrui
    Liu, Zhongying
    RSC ADVANCES, 2021, 11 (13) : 7416 - 7416
  • [35] Galectin-9 and Tim-3 are upregulated in response to microglial activation induced by the peptide Amyloid-β (25-35)
    Hernandez, Eleazar Ramirez
    Zimbron, Luis Fernando Hernandez
    Perez, Emmanuel Segura
    Salgado, Joe Luis Sanchez
    Morales, Mohamed Ali Pereyra
    Zenteno, Edgar
    NEUROPEPTIDES, 2024, 105
  • [36] Alzheimer's type amnesia, neurodegeneration and oxidative stress in the brain induced by ICV administration.: Of β-amyloid peptide (25-35) to rats
    Stepanichev, M
    Victorov, I
    Onufriev, M
    Mitrokhina, O
    Moiseeva, Y
    Lazareva, N
    Gulyaeva, N
    EUROPEAN JOURNAL OF NEUROSCIENCE, 1998, 10 : 94 - 94
  • [37] Cytotoxicity of prion protein peptide (PrP106-126) differs in mechanism from the cytotoxic activity of the Alzheimer's disease amyloid peptide, A beta 25-35
    Hope, J
    Shearman, MS
    Baxter, HC
    Chong, A
    Kelly, SM
    Price, NC
    NEURODEGENERATION, 1996, 5 (01): : 1 - 11
  • [38] Neuroprotection by hypothalamic peptide proline-rich peptide-1 in Aβ25-35 model of Alzheimer's disease
    Galoyan, Armen A.
    Sarkissian, John S.
    Chavushyan, Vergineh A.
    Meliksetyan, Irina B.
    Avagyan, Zaruhi E.
    Poghosyan, Mikhail V.
    Vahradyan, Hasmik G.
    Mkrtchian, Hovhannes H.
    Abrahamyan, Davit O.
    ALZHEIMERS & DEMENTIA, 2008, 4 (05) : 332 - 344
  • [39] Neuroprotective effects of salvianolic acid B on an Aβ25-35 peptide-induced mouse model of Alzheimer's disease
    Lee, Young Woo
    Kim, Dong Hyun
    Jeon, Su Jin
    Park, Se Jin
    Kim, Jong Min
    Jung, Jun Man
    Lee, Hyung Eun
    Bae, Shin Gil
    Oh, Hee Kyong
    Son, Kun Ho Ho
    Ryu, Jong Hoon
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 704 (1-3) : 70 - 77
  • [40] Intranasal formulation of erythropoietin (EPO) showed potent protective activity against amyloid toxicity in the Aβ25-35 non-transgenic mouse model of Alzheimer's disease
    Maurice, Tangui
    Mustafa, Muhammad-Hariri
    Desrumaux, Catherine
    Keller, Emeline
    Naert, Gaelle
    Garcia-Barcelo, Maria de la C.
    Rodriguez Cruz, Yamila
    Garcia Rodriguez, Julio Cesar
    JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (11) : 1044 - 1057